PureTech Health plc
PureTech Health plc (PRTC): 5 pipeline candidates · 1 upcoming catalyst · ~7 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
7.0 months
D/E 0.48 · 0% dilution
Lead: Phase 3
5 candidates
1 upcoming, next in ~1109d
N/A
A transparent, data-derived signal for PureTech Health plcacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$424.0M
Cash
$280.6M
Quarterly Burn
$134.4M
Runway
7.0 mo
Revenue
$4.8M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| deupirfenidone | Phase 3 |
| deupirfenidone | Phase 1 |
| lyt-200 | Phase 1 |
| nintedanib 150 mg [ofev] | Phase 1 |
| pirfenidone | Phase 3 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
3
Total value held
$1.9M
| Holder | Shares | Value |
|---|---|---|
| pentwater capital management lp | 70,000 | $1.0M |
| millennium management llc | 59,525 | $883K |
| diadema partners lp | 7,924 | $11K |
Frequently asked questions
How many drug candidates are in PureTech Health plc's pipeline?
PureTech Health plc (PRTC) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is PureTech Health plc's lead drug candidate?
PureTech Health plc's most advanced tracked candidate is deupirfenidone (Phase 3) for Idiopathic Pulmonary Fibrosis (IPF); Idiopathic Pulmonary Fibrosis; Pharmacokinetic Analysis.
What is PureTech Health plc's next catalyst?
PureTech Health plc's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Double-Blind, Head-to-Head Phase 3 Trial to Evaluate the Efficacy and Safety of LYT-10" — expected July 1, 2029.
What is PureTech Health plc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, PureTech Health plc has approximately 7.0 months of cash runway.
What is PureTech Health plc's market capitalization?
PureTech Health plc's market capitalization is approximately $424.0M.
Get the full picture on PureTech Health plc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.